Dr. Allison Lipitz-Snyderman is a health services researcher in the Department of Epidemiology and Biostatistics at Memorial Sloan Kettering. She is a member of the MSK Center for Health Policy and Outcomes. Objectives of her research are to: 1) Develop novel approaches to measuring the quality and safety of health care; 2) Identify unwarranted variation between health care providers in their practice and outcomes of cancer care; and 3) Evaluate the impact of changes in the health care delivery system on patient outcomes. She has expertise directing studies using data sources including large-scale national claims, cancer registries, and electronic medical records. She also serves as Co-chair of the MSK Cancer Alliance Cancer Control and Population Sciences Sub-committee. Her research has been supported by the National Cancer Institute, the National Comprehensive Cancer Network, the National Institute for Healthcare Management Foundation, and AARP/NQF/OptumLabs, among others.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Allison Lipitz-Snyderman discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.